Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma: a multicenter cooperative study in Japan.

Angioimmunoblastic T-cell lymphoma (AITL) is a major type of peripheral T-cell lymphoma (PTCL). To elucidate the clinicopathologic characteristics and prognosis of AITL in Japan, we retrospectively analyzed 207 patients with AITL. The median patient age was 67 years (range, 34-91 years), with 73% of patients older than 60 years. With a median follow-up of 42 months in surviving patients, 3-year overall survival (OS) was 54% and progression-free survival (PFS) was 38%. The International Prognostic Index (IPI) and the prognostic index for PTCL, not otherwise specified (PIT) were predictive for OS in this analysis. Multivariate analysis found that age older than 60 years, elevated white blood cell (WBC) and IgA levels, the presence of anemia and thrombocytopenia, and extranodal involvement at > 1 site were significant prognostic factors for OS, and IgA, anemia, and mediastinal lymphadenopathy were significant prognostic factors for PFS. A novel prognostic model consisting of the prognostic factors for OS was successfully constructed. In conclusion, IPI and PIT were still useful for prognostication of AITL, and other factors, including those not used in IPI, such as IgA, anemia, WBC count, thrombocytopenia, and mediastinal lymphadenopathy, also significantly affected prognosis. Future investigations for IgA as a unique prognostic factor are warranted.

[1]  K. Ohshima,et al.  Pretreatment total serum protein is a significant prognostic factor for the outcome of patients with peripheral T/natural killer-cell lymphomas , 2010, Leukemia & lymphoma.

[2]  P. Gaulard,et al.  Advances in the understanding and management of angioimmunoblastic T‐cell lymphoma , 2010, British journal of haematology.

[3]  W. Chan,et al.  Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. , 2010, Blood.

[4]  J. Roujeau,et al.  Atypical linear IgA dermatosis revealing angioimmunoblastic T-cell lymphoma. , 2009, Archives of dermatology.

[5]  H. Ueno,et al.  A T cell-dependent mechanism for the induction of human mucosal homing immunoglobulin A-secreting plasmablasts. , 2009, Immunity.

[6]  D. Weisenburger,et al.  International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  H. Nakamine,et al.  Clinico‐pathologic features and outcome of Japanese patients with peripheral T‐cell lymphomas , 2008, Hematological oncology.

[8]  P. Gaulard,et al.  Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. , 2008, Blood.

[9]  W. Klapper,et al.  Expression of two markers of germinal center T cells (SAP and PD-1) in angioimmunoblastic T-cell lymphoma. , 2007, Haematologica.

[10]  Christian Gisselbrecht,et al.  The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. , 2007, Blood.

[11]  G. Freeman,et al.  Programmed Death-1 (PD-1) is a Marker of Germinal Center-associated T Cells and Angioimmunoblastic T-Cell Lymphoma , 2006, The American journal of surgical pathology.

[12]  S. Pileri,et al.  Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  C. Copie-Bergman,et al.  Expression of CXCL13 by Neoplastic Cells in Angioimmunoblastic T-Cell Lymphoma (AITL): A New Diagnostic Marker Providing Evidence That AITL Derives From Follicular Helper T Cells , 2006, The American journal of surgical pathology.

[14]  Y. Kagami,et al.  Clinicopathologic and Prognostic Significance of Cytotoxic Molecule Expression in Nodal Peripheral T-Cell Lymphoma, Unspecified , 2005, The American journal of surgical pathology.

[15]  E. Iannitto,et al.  Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. , 2004, Blood.

[16]  A. Dogan,et al.  Angioimmunoblastic T‐cell lymphoma , 2003, British journal of haematology.

[17]  P. Isaacson,et al.  Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10. , 2002, Blood.

[18]  Koichiro Nakamura,et al.  Leukocytoclastic Vasculitis with IgA Deposits in Angioimmunoblastic T Cell Lymphoma , 2001, The Journal of dermatology.

[19]  M. Engelhard,et al.  Angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma: prognostic impact of clinical observations and laboratory findings at presentation. The Kiel Lymphoma Study Group. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[21]  R. Warnke,et al.  Clonal T-cell populations in angioimmunoblastic lymphadenopathy and angioimmunoblastic lymphadenopathy-like lymphoma. , 1986, The American journal of pathology.

[22]  D. Dorfman,et al.  Germinal-center T-helper-cell markers PD-1 and CXCL13 are both expressed by neoplastic cells in angioimmunoblastic T-cell lymphoma. , 2009, American journal of clinical pathology.

[23]  H. Müller-Hermelink,et al.  Angioimmunoblastic T cell lymphoma is derived from mature T‐helper cells with varying expression and loss of detectable CD4 , 2003, International journal of cancer.

[24]  Y. Kagami,et al.  Clinicopathologic, immunophenotypic, and immunogenotypic analyses of immunoblastic lymphadenopathy-like T-cell lymphoma. , 1988, Blood.

[25]  R. D. Hunter,et al.  WHO Handbook for Reporting Results of Cancer Treatment , 1980 .